Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price rose 3.8% during trading on Wednesday . The stock traded as high as $10.99 and last traded at $10.87, with a volume of 88,983 shares trading hands. The stock had previously closed at $10.47.

AIMT has been the topic of several research reports. Piper Jaffray Cos. restated an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a research note on Tuesday, April 12th. Wedbush restated an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Bank of America Corp. restated a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Finally, Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday, May 20th. Five equities research analysts have rated the stock with a buy rating, Aimmune Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $33.40.

The company’s market cap is $427.54 million. The stock’s 50-day moving average is $13.17 and its 200-day moving average is $14.72.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.03. Equities research analysts expect that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Other institutional investors have made changes to their positions in the company. Aisling Capital LLC raised its position in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares during the period. TLP Group LLC acquired a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000. Eagle Asset Management Inc. purchased a new position in Aimmune Therapeutics during the fourth quarter valued at about $15,794,000. Finally, Alps Advisors Inc. purchased a new position in Aimmune Therapeutics during the fourth quarter valued at about $1,027,000.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.